OncoMatch/Clinical Trials/NCT07662369
CD45RA-depleted DLI for the Treatment of Refractory/Persistent Viral Infections After Haploidentical Transplantation
Is NCT07662369 recruiting? Yes, currently enrolling (Jul 2026). This Phase 1/2 trial studies CD45RA depleted donor lymphocyte infusion (DLI) for hematologic malignancy.
Treatment: CD45RA depleted donor lymphocyte infusion (DLI) — The goal of this clinical trial is to learn whether giving patients special donor immune cells (called "CD45RA Depleted DLI") can help treat viral infections that have not improved with standard antiviral drugs. These infections occur after a stem cell transplant. The study will also look at the safety of this treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Prior therapy
Must have received: hematopoietic stem cell transplantation
Patients who have undergone hematopoietic stem cell transplantation
Must have received: first-line antiviral therapy
Patients who, after ≥2 weeks of first-line therapy, have persistent viral positivity, no relief or worsening of clinical symptoms, or re-infection with the same pathogen after viral clearance
Lab requirements
Kidney function
BUN and Cr ≤ 1.25 × ULN
Liver function
ALT and AST ≤ 10 × upper limit of normal (ULN), TBIL ≤ 5 × ULN
Cardiac function
No cardiac insufficiency on electrocardiogram (ECG) or echocardiogram
Adequate organ function, meeting the following laboratory criteria: Liver function: ALT and AST ≤ 10 × upper limit of normal (ULN), TBIL ≤ 5 × ULN. Renal function: BUN and Cr ≤ 1.25 × ULN. No cardiac insufficiency on electrocardiogram (ECG) or echocardiogram. Pulmonary function: oxygen saturation > 90% on room air.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07662369 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received hematopoietic stem cell transplantation and first-line antiviral therapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify